Clinical Trials Logo

Astrocytoma, Grade II clinical trials

View clinical trials related to Astrocytoma, Grade II.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03906448 Terminated - Clinical trials for Astrocytoma, Grade III

FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma

FORWARD
Start date: May 20, 2019
Phase: Phase 2
Study type: Interventional

This is a phase 2, multi-institutional, historically-controlled, study of 100 patients with newly diagnosed Grade II and III astrocytoma comparing the combination of TTFields with adjuvant temozolomide versus temozolomide alone in historical controls after the completion of definitive chemoradiotherapy. Study treatment may continue past first tumor recurrence. The primary endpoint will be overall survival.

NCT ID: NCT02924038 Terminated - Glioma Clinical Trials

A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)

Start date: April 3, 2017
Phase: Phase 1
Study type: Interventional

This is a pilot, randomized, two arm neoadjuvant vaccine study in human leukocyte antigen-A2 positive (HLA-A2+) adults with World Health Organization (WHO) grade II glioma, for which surgical resection of the tumor is clinically indicated. Co-primary objectives are to determine: 1) the safety of the novel combination of subcutaneously administered IMA950 peptides and poly-ICLC (Hiltonol) and i.v. administered CDX-1127 (Varlilumab) in the neoadjuvant approach; and 2) whether addition of i.v. CDX-1127 (Varlilumab) increases the response rate and magnitude of CD4+ and CD8+ T-cell responses against the IMA950 peptides in post-vaccine peripheral blood mononuclear cell (PBMC) samples obtained from participating patients.

NCT ID: NCT01836549 Terminated - Glioblastoma Clinical Trials

Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors

Start date: March 2013
Phase: Phase 2
Study type: Interventional

This molecular biology and phase II trial studies how well imetelstat sodium works in treating younger patients with recurrent or refractory brain tumors. Imetelstat sodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.